About Binish Chudgar

Mr. Chudgar first held the reins of Intas in the early 1990s, where he led strategic growth and finance. When he joined Intas Pharmaceuticals, the company’s turnover was less than $1 million. Today, Intas is a $1.7 billion multinational organization rapidly rising up the ranks across more than 85 countries.
Mr. Chudgar is always looking to “what next” and has been instrumental in making Intas a “future ready” organisation.

Expanding Potential & Presence
Over the years, he has driven the strategic expansion of the company’s product basket as well as market presence. In the domestic market, Intas is ranked at 10th and enjoys leadership positions in several chronic disease segments. Intas has setup a network of subsidiaries under the umbrella name of Accord Healthcare for global markets, mainly the US and Europe. It is ranked among the top 10 pharmaceutical companies in the US generics market by prescription volume and has the widest European presence amongst Indian pharmaceutical multinationals. In 2017, private equity firm ChrysCapital sold the company’s 3% for INR6900 million, thus valuing the firm at US$3.5 billion, making Intas the country’s most valued privately-held pharmaceuticals company. Intas is currently growing with ~20% CAGR over the last five years, with 70% of revenues coming from international operations.

A Game Changer
Mr. Chudgar’s most defining moment as Intas’ leader was the landmark acquisition of Actavis UK Ltd. & Actavis Ireland Ltd. from Teva Pharmaceutical Industries Ltd. for a deal worth ~£600 million, which was the largest inward investment by an Indian company into the UK since the EU referendum. It has more than doubled Intas’ pan-European operations, making Intas a top 20 generics player globally and
amongst the top 3 players in the UK and Ireland Generics Market.

Envisioning the Future
By continuing his aggressive strategies and acquisitions, he is determined to lead Intas amongst
top 5 Indian pharmaceutical companies by 2020.